Clinical Trial

A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-11-21; most recent amendment 2026-06-22.
Status change: Not Yet Recruiting → Recruiting 2026-01-20
Trial Details
NCT Number NCT07258836
Lead Sponsor Eli Lilly and Company
Conditions Neoplasms, Healthy
Enrollment 41 participants
Start Date 2025-12-22
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-06